Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | CCNC | P24863 | 2/20 | 0.48 |
| ▸ | CDK8 | P49336 | 2/20 | 0.48 |
| ▸ | NCF1 | P14598 | 1/20 | 0.47 |
| ▸ | GAK | O14976 | 1/20 | 0.46 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.46 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.46 |
| ▸ | STK16 | O75716 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.46 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.46 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28650060 | 0.87 | SLC22A12 (0.49) | SLC22A12SMN1; SMN2CCNCCDK8NCF1 | |
| SCHEMBL30390607 | 0.84 | ALK (0.50) | SLC22A12SMN1; SMN2CCNCCDK8NCF1 | |
| SCHEMBL1496382 | 0.84 | ALK (0.50) | SLC22A12SMN1; SMN2CCNCCDK8NCF1 | |
| SCHEMBL14690611 | 0.79 | SLC22A12 (0.51) | SLC22A12SMN1; SMN2CCNCCDK8NCF1 | |
| SCHEMBL29896761 | 0.79 | SLC22A12 (0.51) | SLC22A12SMN1; SMN2CCNCCDK8NCF1 | |
| SCHEMBL29847401 | 0.79 | HTR1A (0.58) | SLC22A12SMN1; SMN2HTTLMNAALDH1A1 | |
| SCHEMBL873431 | 0.79 | HTR1A (0.58) | SLC22A12SMN1; SMN2HTTLMNAALDH1A1 | |
| SCHEMBL358762 | 0.77 | GAK (0.61) | SLC22A12NCF1GAKEPHB6RIPK2 | |
| SCHEMBL827782 | 0.76 | NR4A2 (0.61) | SMN1; SMN2CCNCCDK8GAKRIPK2 | |
| SCHEMBL359558 | 0.76 | NT5E (0.50) | SLC22A12SMN1; SMN2CCNCCDK8NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110437143-B | Benzyl substituted quinoline and derivative and synthesis method thereof | 湘潭大学 | 2022-08-09 | — | — | CN | claimed |
| CN-109776406-B | Method for cross coupling of ether compound and quinoline derivative | 湘潭大学 | 2021-05-04 | — | — | CN | claimed |
| CN-119931978-A | Application of monoamine oxidase as catalyst in preparation of quinoline nitrogen heterocyclic compound | 河北工业大学 | 2025-05-06 | — | — | CN | disclosed |
| US-20250122203-A1 | ADENOSINE RECEPTOR ANTAGONISTS | CROSSIGNAL THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| CN-113347965-B | TGF-beta inhibitors and prodrugs | 生物医学研究机构基金会 | 2025-02-18 | — | — | CN | disclosed |
| EP-4433485-A1 | ADENOSINE RECEPTOR ANTAGONISTS | Crossignal Therapeutics, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| US-12065444-B2 | Substituted tetrazolo[1,5-a]pyrazines and tetrazolo[1,5-c]pyrimidines as adenosine receptor antagonists | CROSSIGNAL THERAPEUTICS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| CN-118317965-A | Adenosine receptor antagonists | 交信医药研发公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-116376858-A | Application of monoamine oxidase from microorganism as catalyst in preparation of quinoline or quinoline derivative | 浙江大学杭州国际科创中心 | 2023-07-04 | — | — | CN | disclosed |
| WO-2023091604-A1 | ADENOSINE RECEPTOR ANTAGONISTS | CROSSIGNAL THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20230159541-A1 | ADENOSINE RECEPTOR ANTAGONISTS | CROSSIGNAL THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| EP-1565471-B1 | QUINOLINYL-PYRROLOPYRAZOLES | LILLY CO ELI (US) | 2006-10-04 | — | — | EP | disclosed |
| CN-1269820-C | Novel pyrrole derivatives as medicaments | LILLY CO ELI (US) | 2006-08-16 | — | — | CN | disclosed |
| US-7087626-B2 | Pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| US-20060040983-A1 | Quinolinyl-pyrrolopyrazoles | ELI LILLY AND COMPANY (US) | 2006-02-23 | — | — | US | disclosed |
| EP-1565471-A1 | QUINOLINYL-PYRROLOPYRAZOLES | ELI LILLY AND COMPANY (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20050112770-A1 | Method for optical measurement of multi-stranded nucleic acid | FUJI PHOTO FILM CO., LTD. | 2005-05-26 | — | — | US | disclosed |
| CN-1511157-A | Novel pyrrole derivatives as medicaments | — | 2004-07-07 | — | — | CN | disclosed |
| WO-2004048382-A1 | QUINOLINYL-PYRROLOPYRAZOLES | ELI LILLY AND COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
| EP-1362894-A2 | Method for optical measurement of multi-stranded nucleic acid using cyanine dyes | FUJI PHOTO FILM CO., LTD. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040983-A1 | Quinolinyl-pyrrolopyrazoles | SDHA, NQO2, SDHB | SLC22A12 507/4885SMN1; SMN2 1609/4885CCNC 595/4885 |
| US-20250122203-A1 | ADENOSINE RECEPTOR ANTAGONISTS | ADORA2A, ADORA1, ADORA3 | SLC22A12 1945/4885SMN1; SMN2 1547/4885CCNC 3736/4885 |
| US-20230159541-A1 | ADENOSINE RECEPTOR ANTAGONISTS | ADORA2A, ADORA1, ADORA3 | SLC22A12 1945/4885SMN1; SMN2 1547/4885CCNC 3736/4885 |
| US-12065444-B2 | Substituted tetrazolo[1,5-a]pyrazines and tetrazolo[1,5-c]pyrimidines as adenosine receptor antagonists | ADORA2A, ADORA1, P2RX5 | SLC22A12 2201/4885SMN1; SMN2 2925/4885CCNC 2250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.